- Home
- ACRS vs BBOT Comparison
ACRS vs BBOT Comparison
Compare ACRS & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | BBOT |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 442.6M |
| IPO Year | 2015 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ACRS | BBOT |
|---|---|---|
| Price | $3.97 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $10.09 | ★ $23.55 |
| AVG Volume (30 Days) | ★ 3.9M | 607.1K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 99.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $2.51 |
| 52 Week High | $6.60 | $14.87 |
Technical Indicators
Market Signals| Indicator | ACRS | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 24.25 |
| Support Level | $3.18 | N/A |
| Resistance Level | $4.67 | $9.36 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 86.34 | 15.66 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.